Exelixis
EXEL
#1608
Rank
C$14.50 B
Marketcap
$51.81
Share price
-0.76%
Change (1 day)
63.65%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): C$0.94 Billion

According to Exelixis's latest financial reports the company's current earnings are C$2.16 Billion. , an increase over its 2023 earnings that were of C$0.36 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 C$0.96 B164.69%
2023 C$0.36 B9.89%
2022 C$0.33 B-20.33%
2021 C$0.41 B124.82%
2020 C$0.18 B-67.14%
2019 C$0.56 B-11.94%
2018 C$0.63 B185.09%
2017 C$0.22 B-325.82%
2016 -C$98.98 Million-58.12%
2015 -C$0.24 Billion-37.61%
2014 -C$0.38 Billion9.75%
2013 -C$0.35 Billion65.96%
2012 -C$0.21 Billion-291.63%
2011 C$0.10 B-195.59%
2010 -C$0.12 Billion-42.17%
2009 -C$0.2 Billion-18.98%
2008 -C$0.25 Billion-6.99%
2007 -C$0.27 Billion46.3%
2006 -C$0.18 Billion33.25%
2005 -C$0.14 Billion-30.92%
2004 -C$0.2 Billion44.29%
2003 -C$0.14 Billion12.86%
2002 -C$0.12 Billion22.79%
2001 -C$96.75 Million60.14%
2000 -C$60.41 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
C$6.19 B 544.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$11.19 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
C$29.88 B 3,011.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$11.81 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
C$6.49 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
C$24.58 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
C$15.66 B 1,530.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$63.16 Million-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$40.93 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA